Triple-negative breast cancer represents one of oncology's most formidable challenges, with limited treatment options and aggressive progression patterns that have stymied researchers for decades. This malignancy's ability to evade standard hormone-based therapies while maintaining cellular immortality has created an urgent need for novel therapeutic approaches targeting fundamental cancer survival mechanisms.
This research identifies RNase H2, a DNA repair enzyme responsible for removing misplaced RNA building blocks from genomic DNA, as a critical dependency in TNBC cells. The study demonstrates that RNASEH2A, the enzyme's catalytic component, becomes overexpressed in tumor tissue and correlates directly with poor patient outcomes. When researchers blocked RNase H2 function through genetic manipulation or pharmacological inhibition, TNBC cells experienced selective toxicity while healthy breast tissue remained unharmed. Animal models confirmed significant tumor growth suppression following RNase H2 targeting.
The therapeutic mechanism operates through dual pathways: disrupting DNA replication processes while simultaneously activating immune system recognition. RNase H2 inhibition creates accumulating DNA damage that overwhelms cancer cell repair capacity, while leaked DNA fragments trigger innate immune responses and attract tumor-fighting T cells. This dual action proves particularly valuable given TNBC's notorious resistance to single-agent therapies. The approach showed enhanced effectiveness when combined with existing DNA damage drugs like ATR and PARP inhibitors, plus improved responses to immune checkpoint blockade treatments. This convergence of DNA repair disruption with immune activation represents a potentially paradigm-shifting strategy for treating this historically intractable cancer subtype.